CoChat
Sign Up
Cited by 29

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Mammalian legumain - A lysosomal cysteine protease with extracellular functions?

Lunde, Ngoc Nguyen, Bosnjak, Tatjana, Solberg, Rigmor, Johansen, Harald Thidemann·2019·Biochimie
DOI 10.1016/j.biochi.2019.06.002
Open this paper in CoChat — free account

Abstract

The cysteine protease legumain (asparaginyl endopeptidase, AEP) plays important roles in normal physiology but is also associated with several disorders, such as atherosclerosis, osteoporosis, cancer and neurodegenerative diseases. The functional roles of legumain have mainly been associated with the presence in lysosomes where legumain is active and mediates processing of multiple proteins, such as the conversion of single to double chain forms of cysteine cathepsins. However, in recent years, a number of studies point to extracellular roles of legumain in addition to the pivotal roles in the lysosomes. In this review, recent knowledge on novel extracellular functions of this protease will be addressed and new discoveries in relation to the diseases mentioned above will be presented.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biochi.2019.06.002

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 101

  1. Chen, 1997, Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase, J. Biol. Chem., 272, 8090, 10.1074/jbc.272.12.8090 · DOI · Paper page
  2. Halfon, 1998, Autocatalytic activation of human legumain at aspartic acid residues, FEBS Lett., 438, 114, 10.1016/S0014-5793(98)01281-2 · DOI
  3. Solberg, 2015, Legumain expression, activity and secretion are increased during monocyte-to-macrophage differentiation and inhibited by atorvastatin, Biol. Chem., 396, 71, 10.1515/hsz-2014-0172 · DOI
  4. Smith, 2012, Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M, Biochimie, 94, 2590, 10.1016/j.biochi.2012.07.026 · DOI
  5. Ishizaki, 2010, The asparaginyl endopeptidase legumain after experimental stroke, J. Cereb. Blood Flow Metab., 30, 1756, 10.1038/jcbfm.2010.39 · DOI
  6. Dutta, 2016, Development of a selected reaction monitoring mass spectrometry-based assay to detect asparaginyl endopeptidase activity in biological fluids, Oncotarget, 7, 70822, 10.18632/oncotarget.12224 · DOI
  7. Lunde, 2017, Increased levels of legumain in plasma and plaques from patients with carotid atherosclerosis, Atherosclerosis, 257, 216, 10.1016/j.atherosclerosis.2016.11.026 · DOI
  8. Dall, 2016, Structure and function of legumain in health and disease, Biochimie, 122, 126, 10.1016/j.biochi.2015.09.022 · DOI
  9. Wang, 2018, Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy, Kidney Int., 94, 91, 10.1016/j.kint.2017.12.025 · DOI
  10. Chen, 2018, Integrated analysis of long non-coding RNA and mRNA expression profile in pancreatic cancer derived exosomes treated dendritic cells by microarray analysis, J. Cancer, 9, 21, 10.7150/jca.21749 · DOI
  11. Miller, 2011, Asparagine endopeptidase is required for normal kidney physiology and homeostasis, FASEB J., 25, 1606, 10.1096/fj.10-172312 · DOI
  12. Chan, 2009, Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome, Proc. Natl. Acad. Sci. U.S.A., 106, 468, 10.1073/pnas.0809824105 · DOI
  13. Sepulveda, 2009, Critical role for asparagine endopeptidase in endocytic toll-like receptor signaling in dendritic cells, Immunity, 31, 737, 10.1016/j.immuni.2009.09.013 · DOI
  14. Lin, 2014, Functional role of asparaginyl endopeptidase ubiquitination by TRAF6 in tumor invasion and metastasis, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju012 · DOI
  15. Lecaille, 2004, Proteinases participating in the processing and activation of prolegumain in primary cultured rat macrophages, Biol. Chem., 385, 511, 10.1515/BC.2004.060 · DOI
  16. Lunde, 2017, Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions, Biochimie, 139, 27, 10.1016/j.biochi.2017.05.009 · DOI
  17. Haugen, 2013, Nuclear legumain activity in colorectal cancer, PLoS One, 8, 10.1371/journal.pone.0052980 · DOI
  18. Freeley, 2018, Asparaginyl endopeptidase (Legumain) supports human Th1 induction via cathepsin L-mediated intracellular C3 activation, Front. Immunol., 9
  19. Li, 2003, Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo, J. Biol. Chem., 278, 38980, 10.1074/jbc.M305930200 · DOI
  20. Dall, 2012, Activation of legumain involves proteolytic and conformational events, resulting in a context-and substrate-dependent activity profile, Acta Crystallogr. F: Structural Biology and Crystallization Communications, 68, 24, 10.1107/S1744309111048020 · DOI
  21. Alvarez-Fernandez, 1999, Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site, J. Biol. Chem., 274, 19195, 10.1074/jbc.274.27.19195 · DOI · Paper page
  22. Briggs, 2010, Cystatin E/M suppresses legumain activity and invasion of human melanoma, BMC Canc., 10
  23. Farley, 2009, Identification and quantification of protein posttranslational modifications, 725, 10.1016/S0076-6879(09)63040-8 · DOI
  24. Kornfeld, 1985, Assembly of asparagine-linked oligosaccharides, Annu. Rev. Biochem., 54, 631, 10.1146/annurev.bi.54.070185.003215 · DOI
  25. Chen, 2009, Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry, J. Proteome Res., 8, 651, 10.1021/pr8008012 · DOI
  26. Zhao, 2014, Structural analysis of asparaginyl endopeptidase reveals the activation mechanism and a reversible intermediate maturation stage, Cell Res., 24, 344, 10.1038/cr.2014.4 · DOI
  27. Dall, 2015, Structure and mechanism of an aspartimide-dependent peptide ligase in human legumain, Angew. Chem. Int. Ed., 54, 2917, 10.1002/anie.201409135 · DOI
  28. Dall, 2018, Structural and functional analysis of cystatin E reveals enzymologically relevant dimer and amyloid fibril states, J. Biol. Chem., 293, 13151, 10.1074/jbc.RA118.002154 · DOI
  29. Brix, 2015, Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges, Protoplasma, 252, 755, 10.1007/s00709-014-0730-0 · DOI
  30. Sleat, 2006, Identification of sites of mannose 6-phosphorylation on lysosomal proteins, Mol. Cell. Proteom., 5, 686, 10.1074/mcp.M500343-MCP200 · DOI
  31. Hasilik, 2009, Intracellular trafficking of lysosomal proteins and lysosomes, Int. J. Clin. Pharm. Ther., 47, S18
  32. Kornfeld, 1982, Steps in the phosphorylation of the high mannose oligosaccharides of lysosomal enzymes, Ciba Foundation symposium, 138
  33. Brix, 2008, Cysteine cathepsins: cellular roadmap to different functions, Biochimie, 90, 194, 10.1016/j.biochi.2007.07.024 · DOI
  34. Ekström, 2008, Internalization of cystatin C in human cell lines, FEBS J., 275, 4571, 10.1111/j.1742-4658.2008.06600.x · DOI
  35. Dall, 2013, Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation, Proc. Natl. Acad. Sci. U.S.A., 110, 10940, 10.1073/pnas.1300686110 · DOI
  36. Berven, 2013, Autoactivation of prolegumain is accelerated by glycosaminoglycans, Biochimie, 95, 772, 10.1016/j.biochi.2012.11.002 · DOI
  37. Liu, 2003, Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy, Cancer Res., 63, 2957
  38. Zhang, 2015, Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease, Nat. Commun., 6, 10.1038/ncomms9762 · DOI · Paper page
  39. Shirahama-Noda, 2003, Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice, J. Biol. Chem., 278, 33194, 10.1074/jbc.M302742200 · DOI
  40. Morita, 2007, Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells, FEBS Lett., 581, 1417, 10.1016/j.febslet.2007.02.064 · DOI
  41. Yamane, 2002, Legumain from bovine kidney: its purification, molecular cloning, immunohistochemical localization and degradation of annexin II and vitamin D-binding protein, Biochim. Biophys. Acta Protein Struct. Mol. Enzymol., 1596, 108, 10.1016/S0167-4838(02)00209-1 · DOI
  42. Jafari, 2017, Legumain regulates differentiation fate of human bone marrow stromal cells and is altered in postmenopausal osteoporosis, Stem Cell Reports, 8, 373, 10.1016/j.stemcr.2017.01.003 · DOI
  43. Chen, 2001, Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase, Biol. Chem., 382, 777, 10.1515/bchm.2001.382.5.777 · DOI
  44. Ashley, 2016, Six-SOMAmer index relating to immune, protease and angiogenic functions predicts progression in IPF, PLoS One, 11, 10.1371/journal.pone.0159878 · DOI
  45. AbdulHameed, 2014, Systems level analysis and identification of pathways and networks associated with liver fibrosis, PLoS One, 9, 10.1371/journal.pone.0112193 · DOI
  46. Edgington-Mitchell, 2016, Legumain is activated in macrophages during pancreatitis, Am. J. Physiol. Gastrointest. Liver Physiol., 311, G548, 10.1152/ajpgi.00047.2016 · DOI
  47. Glass, 2001, Atherosclerosis. the road ahead, Cell, 104, 503, 10.1016/S0092-8674(01)00238-0 · DOI
  48. Nathan, 2010, Nonresolving inflammation, Cell, 140, 871, 10.1016/j.cell.2010.02.029 · DOI · Paper page
  49. Myasoedova, 2018, Matrix metalloproteinases in pro-atherosclerotic arterial remodeling, J. Mol. Cell. Cardiol., 123, 159, 10.1016/j.yjmcc.2018.08.026 · DOI
  50. Johnson, 2017, Metalloproteinases in atherosclerosis, Eur. J. Pharmacol., 816, 93, 10.1016/j.ejphar.2017.09.007 · DOI
  51. Weiss-Sadan, 2017, Cysteine proteases in atherosclerosis, FEBS J., 284, 1455, 10.1111/febs.14043 · DOI
  52. Wu, 2018, Cysteine protease cathepsins in atherosclerotic cardiovascular diseases, J. Atheroscler. Thromb., 25, 111, 10.5551/jat.RV17016 · DOI
  53. Papaspyridonos, 2006, Novel candidate genes in unstable areas of human atherosclerotic plaques, Arterioscler. Thromb. Vasc. Biol., 26, 1837, 10.1161/01.ATV.0000229695.68416.76 · DOI
  54. Clerin, 2008, Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis, Atherosclerosis, 201, 53, 10.1016/j.atherosclerosis.2008.01.016 · DOI
  55. Mattock, 2010, Legumain and cathepsin-L expression in human unstable carotid plaque, Atherosclerosis, 208, 83, 10.1016/j.atherosclerosis.2009.07.022 · DOI
  56. Ammirati, 2017, Clinical relevance of biomarkers for the identification of patients with carotid atherosclerotic plaque: potential role and limitations of cysteine protease legumain, Atherosclerosis, 257, 248, 10.1016/j.atherosclerosis.2017.01.003 · DOI
  57. Bai, 2019, Macrophage-derived legumain promotes pulmonary hypertension by activating the MMP (matrix metalloproteinase)-2/TGF (transforming growth factor)-beta1 signaling, Arterioscler. Thromb. Vasc. Biol., 39, e130, 10.1161/ATVBAHA.118.312254 · DOI
  58. Yu, 2013, Foam cells in atherosclerosis, Clin. Chim. Acta, 424, 245, 10.1016/j.cca.2013.06.006 · DOI
  59. Chistiakov, 2017, Mechanisms of foam cell formation in atherosclerosis, J. Mol. Med. (Berl.), 95, 1153, 10.1007/s00109-017-1575-8 · DOI
  60. Leake, 1997, Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions?, Atherosclerosis, 129, 149, 10.1016/S0021-9150(96)06035-2 · DOI
  61. Halvorsen, 2008, Atherosclerotic plaque stability--what determines the fate of a plaque?, Prog. Cardiovasc. Dis., 51, 183, 10.1016/j.pcad.2008.09.001 · DOI
  62. Libby, 2011, Progress and challenges in translating the biology of atherosclerosis, Nature, 473, 317, 10.1038/nature10146 · DOI · Paper page
  63. Sun, 2018, Legumain suppresses OxLDL-induced macrophage apoptosis through enhancement of the autophagy pathway, Gene, 652, 16, 10.1016/j.gene.2018.02.012 · DOI
  64. Ozawa, 2019, Legumain promotes atherosclerotic vascular remodeling, Int. J. Mol. Sci., 20, 10.3390/ijms20092195 · DOI
  65. van der Meij, 2013, A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation, PLoS One, 8, 10.1371/journal.pone.0053882 · DOI
  66. Wang, 2010, Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients, J. Clin. Pharmacol., 50, 311, 10.1177/0091270009340889 · DOI
  67. Smith, 2014, Simvastatin inhibits glucose metabolism and legumain activity in human myotubes, PLoS One, 9, 10.1371/journal.pone.0085721 · DOI
  68. Kristensen, 2012, Temporal profiling and pulsed SILAC labeling identify novel secreted proteins during ex vivo osteoblast differentiation of human stromal stem cells, Mol. Cell. Proteom., 11, 989, 10.1074/mcp.M111.012138 · DOI
  69. Abdallah, 2005, Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite of extensive proliferation, Biochem. Biophys. Res. Commun., 326, 527, 10.1016/j.bbrc.2004.11.059 · DOI
  70. Kubota, 2003, Proteome analysis of secreted proteins during osteoclast differentiation using two different methods: two-dimensional electrophoresis and isotope-coded affinity tags analysis with two-dimensional chromatography, Proteomics, 3, 616, 10.1002/pmic.200300410 · DOI
  71. Czupalla, 2006, Proteomic analysis of lysosomal acid hydrolases secreted by osteoclasts implications for lytic enzyme transport and bone metabolism, Mol. Cell. Proteom., 5, 134, 10.1074/mcp.M500291-MCP200 · DOI
  72. Choi, 2001, Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment, J. Bone Miner. Res., 16, 1804, 10.1359/jbmr.2001.16.10.1804 · DOI
  73. Edgington-Mitchell, 2015, Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer, Oncotarget, 6, 27008, 10.18632/oncotarget.4714 · DOI
  74. Shorey, 2004, The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula, Bone, 35, 909, 10.1016/j.bone.2004.06.002 · DOI
  75. Zhen, 2015, Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis, Sci. Rep., 5, 10.1038/srep16599 · DOI
  76. Rozhin, 1994, Pericellular pH affects distribution and secretion of cathepsin B in malignant cells, Cancer Res., 54, 6517
  77. Luo, 2006, Targeting tumor-associated macrophages as a novel strategy against breast cancer, J. Clin. Investig., 116, 2132, 10.1172/JCI27648 · DOI
  78. Wu, 2006, Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms, Cancer Res., 66, 970, 10.1158/0008-5472.CAN-05-2591 · DOI
  79. Okamoto, 2019, The functional implications of endothelial gap junctions and cellular mechanics in vascular angiogenesis, Cancers, 11, 10.3390/cancers11020237 · DOI
  80. Urbich, 2011, Proteomic characterization of human early pro-angiogenic cells, J. Mol. Cell. Cardiol., 50, 333, 10.1016/j.yjmcc.2010.11.022 · DOI
  81. Leto, 2018, On the role of cystatin C in cancer progression, Life Sci., 202, 152, 10.1016/j.lfs.2018.04.013 · DOI · Paper page
  82. Li, 2018, Correlation of cystatin E/M with clinicopathological features and prognosis in triple-negative breast cancer, Ann. Clin. Lab. Sci., 48, 40
  83. Cox, 2009, Cystatins and cancer, Front Biosci (Landmark Ed), 14, 463, 10.2741/3255 · DOI
  84. Jin, 2012, Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis, Cell Res., 22, 1356, 10.1038/cr.2012.90 · DOI
  85. McCarthy, 2014, The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions, J. Proteome Res., 13, 3131, 10.1021/pr500146y · DOI
  86. Knezevic, 2009, Variability, heritability and environmental determinants of human plasma N-glycome, J. Proteome Res., 8, 694, 10.1021/pr800737u · DOI
  87. An, 2009, Glycomics and disease markers, Curr. Opin. Chem. Biol., 13, 601, 10.1016/j.cbpa.2009.08.015 · DOI
  88. Marino, 2012, Synthesis of a derivative of alpha-D-Glcp(1->2)-D-Galf suitable for further glycosylation and of alpha-D-Glcp(1->2)-D-Gal, a disaccharide fragment obtained from varianose, Beilstein J. Org. Chem., 8, 2142, 10.3762/bjoc.8.241 · DOI
  89. Edgington, 2013, Functional imaging of legumain in cancer using a new quenched activity-based probe, J. Am. Chem. Soc., 135, 174, 10.1021/ja307083b · DOI
  90. Zhao, 2018, Legumain-specific near-infrared fluorescence “turn on” for tumor-targeted imaging, Anal. Chem., 90, 8732, 10.1021/acs.analchem.8b02704 · DOI
  91. Mai, 2017, Targeting legumain as a novel therapeutic strategy in cancers, Curr. Drug Targets, 18, 1259, 10.2174/1389450117666161216125344 · DOI
  92. Boland, 2018, Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing, Nat. Rev. Drug Discov., 17, 660, 10.1038/nrd.2018.109 · DOI
  93. Øverbye, 2011, Autophagic activity measured in whole rat hepatocytes as the accumulation of a novel BHMT fragment (p10), generated in amphisomes by the asparaginyl proteinase, legumain, Autophagy, 7, 1011, 10.4161/auto.7.9.16436 · DOI · Paper page
  94. Kang, 2018, α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease, EMBO J., 37, 10.15252/embj.201798878 · DOI
  95. Herskowitz, 2012, Asparaginyl endopeptidase cleaves TDP-43 in brain, Proteomics, 12, 2455, 10.1002/pmic.201200006 · DOI
  96. Zhang, 2018, δ-Secretase-cleaved Tau stimulates Aβ production via upregulating STAT1-BACE1 signaling in Alzheimer's disease, Mol. Psychiatry
  97. Wang, 2018, Delta-secretase (AEP) mediates tau-splicing imbalance and accelerates cognitive decline in tauopathies, J. Exp. Med., 215, 3038, 10.1084/jem.20180539 · DOI
  98. Liu, 2008, Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase, Mol. Cell, 29, 665, 10.1016/j.molcel.2008.02.017 · DOI
  99. Forester, 2010, Age-related changes in brain energetics and phospholipid metabolism, NMR Biomed., 23, 242, 10.1002/nbm.1444 · DOI
  100. Fang, 2010, Hypothesis on the relationship between the change in intracellular pH and incidence of sporadic alzheimer's disease or vascular dementia, Int. J. Neurosci., 120, 591, 10.3109/00207454.2010.505353 · DOI
  101. Zhang, 2016, Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases, Expert Opin. Ther. Targets, 20, 1237, 10.1080/14728222.2016.1182990 · DOI

Cited by

Sorted by citations

Metadata

Authors
Lunde, N. N., Bosnjak, T., Solberg, R., & Johansen, H. T.
ORCID
Lunde, Ngoc Nguyen
Venue
Biochimie
Publisher
Elsevier BV
Published
2019-11
Volume
166
Pages
77-83
ISSN
0300-9084
DOI
10.1016/j.biochi.2019.06.002
Cited by
29
References
1
Language
en
Licence
Funders
Universitetet i Oslo

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review